>AT5G05410.1 |  DREB2A DNA binding / transcription activator/ transcription factor 
MAVYDQSGDRNRTQIDTSRKRKSRSRGDGTTVAERLKRWKEYNETVEEVSTKKRKVPAKG 
SKKGCMKGKGGPENSRCSFRGVRQRIWGKWVAEIREPNRGSRLWLGTFPTAQEAASAYDE 
AAKAMYGPLARLNFPRSDASEVTSTSSQSEVCTVETPGCVHVKTEDPDCESKPFSGGVEP 
MYCLENGAEEMKRGVKADKHWLSEFEHNYWSDILKEKEKQKEQGIVETCQQQQQDSLSVA 
DYGWPNDVDQSHLDSSDMFDVDELLRDLNGDDVFAGLNQDRYPGNSVANGSYRPESQQSG 
FDPLQSLNYGIPPFQLEGKDGNGFFDDLSYLDLEN*
>AT5G05410.1 |  DREB2A DNA binding / transcription activator/ transcription factor 
MAVYDQSGDRNRTQIDTSRKRKSRSRGDGTTVAERLKRWKEYNETVEEVSTKKRKVPAKG 
SKKGCMKGKGGPENSRCSFRGVRQRIWGKWVAEIREPNRGSRLWLGTFPTAQEAASAYDE 
AAKAMYGPLARLNFPRSDASEVTSTSSQSEVCTVETPGCVHVKTEDPDCESKPFSGGVEP 
MYCLENGAEEMKRGVKADKHWLSEFEHNYWSDILKEKEKQKEQGIVETCQQQQQDSLSVA 
DYGWPNDVDQSHLDSSDMFDVDELLRDLNGDDVFAGLNQDRYPGNSVANGSYRPESQQSG 
FDPLQSLNYGIPPFQLEGKDGNGFFDDLSYLDLEN*
>AT5G05410.2 |  DREB2A DNA binding / transcription activator/ transcription factor 
MAVYDQSGDRNRTQIDTSRKRKSRSRGDGTTVAERLKRWKEYNETVEEVSTKKRKVPAKG 
SKKGCMKGKGGPENSRCSFRGVRQRIWGKWVAEIREPNRGSRLWLGTFPTAQEAASAYDE 
AAKAMYGPLARLNFPRSDASEVTSTSSQSEVCTVETPGCVHVKTEDPDCESKPFSGGVEP 
MYCLENGAEEMKRGVKADKHWLSEFEHNYWSDILKEKEKQKEQGIVETCQQQQQDSLSVA 
DYGLNQDRYPGNSVANGSYRPESQQSGFDPLQSLNYGIPPFQLEGKDGNGFFDDLSYLDL 
EN*
>AT5G05410.2 |  DREB2A DNA binding / transcription activator/ transcription factor 
MAVYDQSGDRNRTQIDTSRKRKSRSRGDGTTVAERLKRWKEYNETVEEVSTKKRKVPAKG 
SKKGCMKGKGGPENSRCSFRGVRQRIWGKWVAEIREPNRGSRLWLGTFPTAQEAASAYDE 
AAKAMYGPLARLNFPRSDASEVTSTSSQSEVCTVETPGCVHVKTEDPDCESKPFSGGVEP 
MYCLENGAEEMKRGVKADKHWLSEFEHNYWSDILKEKEKQKEQGIVETCQQQQQDSLSVA 
DYGLNQDRYPGNSVANGSYRPESQQSGFDPLQSLNYGIPPFQLEGKDGNGFFDDLSYLDL 
EN*
>AT1G68560.1 |  XYL1 (ALPHA-XYLOSIDASE 1) alpha-N-arabinofuranosidase/ hydrolase hydrolyzing O-glycosyl compounds / xylan 14-beta-xylosidase 
MASSSSSLAFSLSLLLALILCFSPTQSYKTIGKGYRLVSIEESPDGGFIGYLQVKQKNKI 
YGSDITTLRLFVKHETDSRLRVHITDAKQQRWEVPYNLLPREQPPQVGKVIGKSRKSPIT 
VQEISGSELIFSYTTDPFTFAVKRRSNHETLFNTTSSLVFKDQYLEISTSLPKEASLYGL 
GENSQANGIKLVPNEPYTLYTEDVSAINLNTDLYGSHPMYMDLRNVGGKAYAHAVLLLNS 
NGMDVFYRGDSLTYKVIGGVFDFYFIAGPSPLNVVDQYTQLIGRPAPMPYWSLGFHQCRW 
GYHNLSVVEDVVDNYKKAKIPLDVIWNDDDHMDGHKDFTLNPVAYPRAKLLAFLDKIHKI 
GMKYIVINDPGIGVNASYGTFQRAMAADVFIKYEGKPFLAQVWPGPVYFPDFLNPKTVSW 
WGDEIKRFHDLVPIDGLWIDMNEVSNFCSGLCTIPEGKQCPSGEGPGWVCCLDCKNITKT 
RWDDPPYKINATGVVAPVGFKTIATSATHYNGVREYDAHSIYGFSETIATHKGLLNVQGK 
RPFILSRSTFVGSGQYAAHWTGDNQGTWQSLQVSISTMLNFGIFGVPMVGSDICGFYPQP 
TEELCNRWIEVGAFYPFSRDHANYYSPRQELYQWDTVADSARNALGMRYKILPFLYTLNY 
EAHMTGAPIARPLFFSFPEYTECYGNSRQFLLGSSFMISPVLEQGKTEVEALFPPGSWYH 
MFDMTQAVVSKNGKRVTLPAPLNFVNVHLYQNTILPTQQGGLISKDARTTPFSLVIAFPA 
GASEGYATGKLYLDEDELPEMKLGNGQSTYVDFYASVGNGTMKMWSQVKEGKFALSKGWV 
IEKVSVLGLRGAGQVSEIQINGSPMTKKIEVSSKEHTYVIGLEDEEENKSVMVEVRGLEM 
LVGKDFNMSWKMGIN*
>AT5G11720.1 |  alpha-glucosidase 1 (AGLU1) 
MSSLHWFPNIFIVVVVFFSLRSSQVVLEEEESTVVGYGYVVRSVGVDSNRQVLTAKLDLI 
KPSSVYAPDIKSLNLHVSLETSERLRIRITDSSQQRWEIPETVIPRAGNHSPRRFSTEED 
GGNSPENNFLADPSSDLVFTLHNTTPFGFSVSRRSSGDILFDTSPDSSDSNTYFIFKDQF 
LQLSSALPENRSNLYGIGEHTKRSFRLIPGETMTLWNADIGSENPDVNLYGSHPFYMDVR 
GSKGNEEAGTTHGVLLLNSNGMDVKYEGHRITYNVIGGVIDLYVFAGPSPEMVMNQYTEL 
IGRPAPMPYWSFGFHQCRYGYKNVSDLEYVVDGYAKAGIPLEVMWTDIDYMDGYKDFTLD 
PVNFPEDKMQSFVDTLHKNGQKYVLILDPGIGVDSSYGTYNRGMEADVFIKRNGEPYLGE 
VWPGKVYFPDFLNPAAATFWSNEIKMFQEILPLDGLWIDMNELSNFITSPLSSGSSLDDP 
PYKINNSGDKRPINNKTVPATSIHFGNISEYDAHNLYGLLEAKATHQAVVDITGKRPFIL 
SRSTFVSSGKYTAHWTGDNAAKWEDLAYSIPGILNFGLFGIPMVGADICGFSHDTTEELC 
RRWIQLGAFYPFARDHSSLGTARQELYLWDSVASSARKVLGLRMRLLPHLYTLMYEAHVS 
GNPIARPLFFSFPQDTKTYEIDSQFLIGKSIMVSPALKQGAVAVDAYFPAGNWFDLFNYS 
FAVGGDSGKHVRLDTPADHVNVHVREGSIVAMQGEALTTRDARKTPYQLLVVASRLENIS 
GELFLDDGENLRMGAGGGNRDWTLVKFRCYVTGKSVVLRSEVVNPEYASKMKWSIGKVTF 
VGFENVENVKTYEVRTSERLRSPRISLIKTVSDNDDPRFLSVEVSKLSLLVGKKFEMRLR 
LT*
>AT3G45940.1 |  alpha-xylosidase putative 
MASCLSLLVAIILCFSSLQCSNAIGKGYRLISMEKSPDDGSFIGYLQVKQSNKIYGSDIT 
ILRLFINYRTDHRLRVHITDAKKQRWEVPYNLLRREQPPNVIGKSRKSPVTVQEISGPEL 
ILIFTVDPFSFAVRRRSNGETIFNTSSSDESFGEMVFKDQYLEISTSLPKDASLYGFGEN 
SQANGIKLVPNEPYTLFTEDVSAFNLNTDLYGSHPVYMDLRNVSGKAYAHSVLLLNSHGM 
DVFYRGDSLTYKVIGGVFDFYFFAGPSPLNVVDQYTSLIGRPAPMPYWSLGFHQCRWGYR 
NVSVVKDVVDNYQKAKIPLDVIWNDADYMDGYKDFTLDLVNFPHAKLLSFLDRIHKMGMK 
YVVIKDPGIGVNASYGVYQRGMASDVFIKYEGKPFLAQVWPGPVYFPDFLNPKTVSWWGD 
EIRRFHELVPIDGLWIDMNEINATGHKASLGFKTIPTSAYHYNGVREYDAHSIYGFSEAI 
ATHKALLAVQGKRPFILSRSTFVGSGQYAAHWTGDNQGTWQSLQVSISTMLNFGIFGVPM 
VGSDICGFFPPTPEELCNRWIEVGAFYPFSRDHADYYAPRKELYQWGTVAESARNALGMR 
YKLLPFLYTLNYEAHMSGAPIARPLFFSFPEFTECYGLSKQFLLGSSLMISPVLEQGKTQ 
VEALFPPGSWYHMFDMTQVVVSKNGRLFTLPAPFNVVNVHLYQNAILPMQQVVAFPAGAS 
EGYASGKLFLDDDELPEMKLGNGKSTYIDFYASVGNESVKIWSQVKEGQFALSQGLVIEK 
VIVLGLKGTWKVSEILLNGSSISNETKTIEVSSKEQMYVVGSEDEGESKSFMVELKGLEM 
LVGKDFNISWKMASTNVLSMAGNEVIAR*
>AT5G65560.1 |  pentatricopeptide (PPR) repeat-containing protein 
MIRRIQPRCNSGLTGSVSAFEVLKKKFSTDVTVPSPVTRRQFCSVSPLLRNLPEEESDSM 
SVPHRLLSILSKPNWHKSPSLKSMVSAISPSHVSSLFSLDLDPKTALNFSHWISQNPRYK 
HSVYSYASLLTLLINNGYVGVVFKIRLLMIKSCDSVGDALYVLDLCRKMNKDERFELKYK 
LIIGCYNTLLNSLARFGLVDEMKQVYMEMLEDKVCPNIYTYNKMVNGYCKLGNVEEANQY 
VSKIVEAGLDPDFFTYTSLIMGYCQRKDLDSAFKVFNEMPLKGCRRNEVAYTHLIHGLCV 
ARRIDEAMDLFVKMKDDECFPTVRTYTVLIKSLCGSERKSEALNLVKEMEETGIKPNIHT 
YTVLIDSLCSQCKFEKARELLGQMLEKGLMPNVITYNALINGYCKRGMIEDAVDVVELME 
SRKLSPNTRTYNELIKGYCKSNVHKAMGVLNKMLERKVLPDVVTYNSLIDGQCRSGNFDS 
AYRLLSLMNDRGLVPDQWTYTSMIDSLCKSKRVEEACDLFDSLEQKGVNPNVVMYTALID 
GYCKAGKVDEAHLMLEKMLSKNCLPNSLTFNALIHGLCADGKLKEATLLEEKMVKIGLQP 
TVSTDTILIHRLLKDGDFDHAYSRFQQMLSSGTKPDAHTYTTFIQTYCREGRLLDAEDMM 
AKMRENGVSPDLFTYSSLIKGYGDLGQTNFAFDVLKRMRDTGCEPSQHTFLSLIKHLLEM 
KYGKQKGSEPELCAMSNMMEFDTVVELLEKMVEHSVTPNAKSYEKLILGICEVGNLRVAE 
KVFDHMQRNEGISPSELVFNALLSCCCKLKKHNEAAKVVDDMICVGHLPQLESCKVLICG 
LYKKGEKERGTSVFQNLLQCGYYEDELAWKIIIDGVGKQGLVEAFYELFNVMEKNGCKFS 
SQTYSLLIEGPPDST*